(firstQuint)Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer.

 This Phase II randomized study is to determine the efficacy and toxicity of Nimotuzumab in combined with chemoradiotherapy for unresectable,local advanced squamous cell lung cancer.

 All patients received five cycles of weekly docetaxel and cisplatin, each of 1 day's duration.

 Thoracic RT includes the delivery of 65 Gy in 25 fractions on weekdays for a total of five weeks.

 Nimotuzumab group was treated with five doses of weekly nimotuzumab (200mg, IV) combined with chemoradiotherapy, while placebo group was treated with five doses of placebos.

 150 patients are needed to be enrolled for an 80% power to detect an improvement in overall survival from 15 months to 25 months.

.

 Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer@highlight

This Phase II randomized study is to determine the efficacy and toxicity of Nimotuzumab in combined with chemoradiotherapy for unresectable,local advanced squamous cell lung cancer.

